Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection
Description:
Host: Mark Socinski, MD
This animated podcast explores the evolving role of ALK inhibitors in managing early-stage non-small cell lung cancer (NSCLC). Dr. Mark Socinski discusses molecular profiling as a cornerstone for identifying ALK fusion–positive cases and highlights clinical data from pivotal trials. He also addresses the challenges of treatment adherence, toxicity management, and the importance of surrogate endpoints in early-stage disease. The discussion concludes with key takeaways on integrating targeted therapies into standard care for early-stage resectable NSCLC.